title: Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation.
abstract: Bacterial intestinal overgrowth syndrome (SIBO) treatment is based on antibiotics. Probiotics have been shown to give similar results, whilst no study is available about prebiotics. This study evaluated the addition of probiotics or prebiotics to antibiotics on SIBO symptoms in a 6-month follow-up. We enrolled 40 patients (14 males and 26 females) reporting abdominal compliant without gastrointestinal diseases/alarm symptoms. SIBO was diagnosed by the agreement of lactulose and glucose breath tests. Patients were randomly divided into two groups homogeneous for sex and age: group 1 received Rifaximin 400 mg/day for 7 days/month followed by Lactobacillus casei for 7 days more and group 2 antibiotic followed by short chain fructo-oligosaccharides. All patients recorded a questionnaire for subjective symptom evaluation according to Rome III criteria and Bristol scale for stool characters before the study and after 6 months.
  
  
  METHODS
  Student's t and Fisher's exact tests. In group 1, a significant improvement was obtained in 5 out of 6 symptoms, whilst in group 2 in 4 out of 6 symptoms (nausea and number of bowel movements failed to improve). Despite we observed a trend of probiotics to be more effective than prebiotics, the difference in the percentage of improved symptoms was not significant (83,3% vs 66.6%; p= 0.57). Our preliminary data show a good outcome with sequential antibioticprobiotic/ prebiotic administration in patients with SIBO.
authors.affiliation: Gastroenterology Section, Department of Medical Sciences, University of Foggia, Foggia, Italy.
authors.forename: Rosa
authors.initials: R
authors.lastname: Rosania
authors.forename: Floriana
authors.initials: F
authors.lastname: Giorgio
authors.forename: Mariabeatrice
authors.initials: M
authors.lastname: Principi
authors.forename: Annacinzia
authors.initials: A
authors.lastname: Amoruso
authors.forename: Rosa
authors.initials: R
authors.lastname: Monno
authors.forename: Alfredo
authors.initials: A
authors.lastname: Di Leo
authors.forename: Enzo
authors.initials: E
authors.lastname: Ierardi
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001765:Blind Loop Syndrome / Q000175:diagnosis / Q000382:microbiology / Q000628:therapy*; D001944:Breath Tests / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D005947:Glucose; D006801:Humans; D007421:Intestine, Small / Q000382:microbiology; D007780:Lacticaseibacillus casei; D007792:Lactulose; D008297:Male; D008875:Middle Aged; D009844:Oligosaccharides / Q000008:administration & dosage; D056692:Prebiotics; D019936:Probiotics / Q000008:administration & dosage / Q000627:therapeutic use*; D012294:Rifamycins / Q000008:administration & dosage / Q000627:therapeutic use; D000078262:Rifaximin; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D009844:Oligosaccharides; D056692:Prebiotics; D012294:Rifamycins; D007792:Lactulose; D005947:Glucose; D000078262:Rifaximin